Table 3.
Factors Associated with Renal Response
| Variable | HR | P-value |
|---|---|---|
|
| ||
| Age (Quartiles) | 0.86 | |
| 45.5–50 | 0.67 (0.21,2.15) | |
| 50–60.75 | 0.87 (0.25,3.03) | |
| >60.75 | 0.61 (0.16,2.34) | |
|
| ||
| Gender (M/F) | 0.85 (0.35,2.02)) | 0.70 |
|
| ||
| Race (Caucasian/African American) | 1 (0.29,3.46) | 0.99 |
|
| ||
| Hypertension (No/Yes) | 1.11 (0.43,2.87) | 0.83 |
|
| ||
| Involved serum free light chain isotype (K/L) | 0.68 (0.15,3.04) | 0.52 |
|
| ||
| MIDD subtype (HCDD/LCDD/LHCDD) | 0.33 | |
| LCDD | 0.38 (0.08,1.73) | |
| LHCDD | 0.91 (0.08,10.25) | |
|
| ||
| 0.75 | ||
| Involved FLC level (quartiles) | 1.13 (0.31,4.09) | |
| 29–105 | 1.89 (0.53,6.8) | |
| 105-240 | 1.04 (0.24,4.43) | |
| >240 | ||
|
| ||
| Involved/Uninvolved FLC ratio (quartiles) | 0.77 | |
| 12.78–66.66 | 1.48 (0.42,5.24) | |
| 66.66–203.58 | 1.86 (0.45,7.66) | |
| >203.58 | 1.02 (0.26,4.02) | |
|
| ||
| 0.51 | ||
| Serum M-protein level (quartiles) | 0.49 (0.13,1.82) | |
| 0.05–0.48 | 1.05 (0.34,3.24) | |
| >0.48 | ||
|
| ||
| Bone marrow plasmacytosis (quartiles) | 0.36 | |
| 12.5–20 | 1.47 (0.54,4.02) | |
| 20–29 | 1.43 (0.17,12.26) | |
| >29 | 0.47 (0.12,1.84) | |
|
| ||
| Serum albumin level (quartiles) | 0.42 | |
| 3.5–3.9 | 1.29 (0.36,4.65) | |
| 3.9–4.2 | 1.27 (0.41,3.99) | |
| >4.2 | 0.42 (0.1,1.74) | |
|
| ||
| Beta 2 microglobulin level (quartiles) | 0.04 | |
| 4.4–5.5 | 0.74 (0.23,2.43) | |
| 5.5–9.01 | 0.98 (0.27,3.6) | |
| >9.01 | 0.13 (0.03,0.66) | |
|
| ||
| Estimated GFR at diagnosis (quartiles) | 0.07 | |
| 10.925–23.2 | 4.7 (1.15,19.22) | |
| 23.2–42.1 | 3.13 (0.73,13.41) | |
| >42.1 | 4.98 (1.25,19.8) | |
|
| ||
| Dialysis prior to treatment (Yes/No) | 0.06 (0.01,0.47) | 0.0004 |
|
| ||
| 24-hr urine protein at diagnosis (quartiles) | 0.49 | |
| 469.25–2488.95 | 0.85 (0.24,2.93) | |
| 2488.95–6002.9 | 1.96 (0.59,6.5) | |
| >6002.9 | 1.5 (0.43,5.26) | |
|
| ||
| Hematuria at diagnosis (Yes/No) | 1.56 (0.51,4.81) | 0.43 |
|
| ||
| Bortezomib-based therapy (Yes/No) | 1.63 (0.61,4.34) | 0.32 |
|
| ||
| Lenalidomide-based therapy (Yes/No) | 0.9 (0.26,3.14) | 0.87 |
|
| ||
| ASCT (Yes/No)* | 0.83 (0.3,2.29) | 0.72 |
|
| ||
| Hematologic response (CR vs <CR)* | 0.62 (0.25,1.54) | 0.29 |
Positive HR is associated with increased probability of response
ASCT, autologous stem cell transplantation; FLC, free light chain; GFR, glomerular filtration rate; HCDD, heavy chain deposition disease; HR, hazard ratio; IQR, interquartile range; K/L, kappa/lambda; LCDD, light chain deposition disease; LHCDD, light and/or heavy chain deposition disease; MIDD; monoclonal immunoglobulin deposition disease; MGUS, monoclonal gammopathy of undetermined significance; MGRS, monoclonal gammopathy of renal significance.
*
Time-dependent covariate.